Toronto, Ontario, Canada, November 2025 — Laetitia Decroix Guilloux has been elevated as President, Johnson & Johnson Innovative Medicine, Canada, marking a new phase of strategic leadership for the company’s Canadian operations. With over 20 years of global healthcare experience, Laetitia brings a proven record of driving growth, fostering innovation, and advancing equitable access to care across diverse international markets.
Laetitia’s journey with Johnson & Johnson spans close to six years, during which she has held several key leadership roles across regions. Most recently, she served as Vice President & Managing Director – TURGAN (Turkey, Ukraine, Georgia, and Azerbaijan), where she led the transformation of the business, achieving a remarkable 65% increase in regional revenue. She successfully steered the organization through political and economic volatility, elevating its market position from #11 to #3 among multinational companies in Turkey, and championed the establishment of the country’s first Healthcare Businesswomen Association (HBA) branch—advancing diversity and empowering women in leadership.
Prior to this, Laetitia served as Vice President, Oncology EMEA Commercial Strategy Lead, based in Belgium, where she led a €1B oncology portfolio across Europe, the Middle East, and Africa. Her strategic leadership in precision medicine and market access drove a 28% CAGR in oncology growth and enabled the successful launch of several breakthrough therapies. Earlier, as Business Unit Head, Oncology & Hematology in France, she delivered 35% year-on-year growth, launching multiple life-saving therapies, including Darzalex, Imbruvica, and Erleada, and preparing markets for next-generation CAR-T and immunotherapy treatments.
Before joining Johnson & Johnson, Laetitia spent nearly a decade at Bristol Myers Squibb, where she held global and regional leadership roles in oncology, including Global Director, Opdivo GI Lead & Business Unit Director, Oncology. She was instrumental in the global success of Opdivo, leading its launch and establishing market leadership in key indications. Her earlier roles with Roche, Novartis, and Merck KGaA gave her a solid foundation in oncology product management, clinical strategy, and cross-functional leadership across Europe.
About Johnson & Johnson Innovative Medicine, Canada
Johnson & Johnson Innovative Medicine, Canada is a part of Johnson & Johnson’s global Innovative Medicine division, advancing breakthrough science to transform human health. The company focuses on discovering, developing, and delivering life-changing treatments across oncology, immunology, neuroscience, cardiovascular, pulmonary hypertension, and other therapeutic areas.
Guided by the mission to lead where medicine is going, Johnson & Johnson Innovative Medicine integrates scientific excellence with compassion to address the world’s most complex diseases. Its Canadian operations play a pivotal role in shaping patient access, advancing healthcare partnerships, and supporting policy frameworks that strengthen Canada’s position as a global leader in healthcare innovation.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
